Background Advanced age at diagnosis is considered a poor prognostic factor in mycosis fungoides (MF) and S ezary
Introduction
The incidence of cutaneous T-cell lymphoma (CTCL) increases with age and peaks in the elderly population with an incidence rate of 36 CTCL cases per million persons in patients over the age of 70 in the United States (US).
1 Mycosis fungoides/S ezary syndrome (MF/SS) is the most common type of primary CTCL. The median age of diagnosis of MF/SS is usually 55-60 years, 2 and the incidence of MF rises relatively sharply with age. 3 Advanced age has been shown to be associated with a more advanced clinical stage at presentation, 4 as well as with worse overall survival (OS), 5 disease-specific survival (DSS) and greater risk of disease progression. [6] [7] [8] [9] The decline of immune system function with age has been suggested to contribute to the high incidence, advanced disease at presentation and poor outcomes in elderly patients with MF/SS. 10 Treatment selection in elderly patients with MF/SS is often challenging due to comorbidities, multiple concurrent medications, impaired functional ability and increased risk of treatment-associated toxicities in this population. 11 Therefore, identification of factors that are relevant to outcome and survival is of specific importance in this age group and may lead to better management and improved survival. A Cutaneous Lymphoma International Prognostic index (CLIPi) has been recently developed for early-and late-stage MF/SS, and it includes age over 60 years at diagnosis as a significant adverse prognostic factor; however, CLIPi utility in elderly patients is unclear. 12 The aim of this study was to evaluate the outcomes in a retrospective cohort of patients who were diagnosed with MF/SS at the age of 65 and older and to evaluate prognostic factors in this age group.
Patients and methods

Patient selection and clinical parameters
We retrospectively searched our institutional cancer registry and pathology database between the years 1992 and 2015 for patients who were diagnosed with MF/SS at the age of 65 or older and were followed at Memorial Sloan Kettering Cancer Center. We included patients with a diagnosis of MF/SS which was confirmed clinically and pathologically at our institution. Patients were excluded if clinical records were incomplete or if they were followed at our institution for less than a year, unless they died within that period. This study was approved by the Institutional Review Board. Medical records were retrospectively reviewed for the following parameters: age at diagnosis, sex, (self-identified) ethnicity, duration between symptom onset and diagnosis, clinical and TNMB classification stage at the time of diagnosis based on the International Society for Cutaneous Lymphoma and Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC) classification, 13 the presence of plaques and/or patches on physical examination and lactate dehydrogenase (LDH) levels. Patients were assigned to the following age groups: 65-74, 75-84 and ≥85. Pathology reports at diagnosis were reviewed for confirmation of folliculotropic MF (FMF) and large cell transformation (LCT). Follow-up records were reviewed for the development of LCT and for the following outcomes: progression to a higher clinical MF/SS stage, death from any cause or due to MF/SS.
Statistical analysis
The date of the first diagnostic biopsy was considered as the date of diagnosis. Overall survival (OS) was calculated from the date of diagnosis to death from any cause or last follow-up. Diseasespecific survival (DSS) was calculated from the date of diagnosis to death from MF/SS, death from another cause or last followup. Progression-free survival (PFS) was defined as the time from diagnosis to progression to a more advanced clinical stage or death from MF/SS disease. Univariate and multivariate analyses of survival and progression risk of prognostic factors were performed using Cox proportional hazards model. Chi-squared test was used to compare proportions, and t-test or Wilcoxon test was used to compare numeric data. Kaplan-Meier curves were calculated for OS, DSS and PFS, and log-rank tests were used to assess equality. All tests were two-sided, and P value <0.05 was considered statistically significant. Statistical analyses were performed using Stata software (version 12.1; StataCorp LP, Huston, TX, USA). Fig. 1 .
Prognostic factors
In a univariate analysis of the entire cohort, OS was significantly worse across the age groups and no significant differences were found for DSS and PFS (Table 1) . Increased age was confirmed to be independently associated with OS and not with DSS or PFS in a multivariate analysis. Overall survival, DSS and PFS were significantly different across clinical stage. OS and PFS differed significantly across T classifications and OS and DSS across B classifications in a univariate analysis. Elevated LDH was significantly correlated with poor outcomes. Univariate analysis of the entire cohort showed no differences in OS, DSS or PFS based on the presence of FMF.
Large cell transformation at the time of diagnosis did not have significant impact on survival. The development of LCT during follow-up, however, was a negative prognostic factor for OS [hazard ratio: (HR) = 1.72, 95% confidence interval: 1.80-7.97, P < 0.001] and DSS (HR = 12.27, 4.25-35.39, P < 0.001) in univariate analysis. Multivariate analysis was performed for OS and showed better OS in females, and worse OS was independently associated with increasing T classification, elevated LDH, B1 compared to B0 classification and development of LCT. Multivariate analysis for PFS showed an independent association of increasing T classification with PFS and not with B classification or elevated LDH.
Prognostic factors in early-and late-stage disease
Prognostic factors were analysed separately for early-and latestage MF/SS patients and are shown in Table 2 . Increasing age was significantly associated with reduced OS but not with DSS or PFS in early-stage disease and was of no prognostic significance in late-stage patients. In a multivariate analysis, increasing age was independently associated with OS in the early-disease group and for patient ≥85 in the late-disease group.
In the early-stage MF/SS group, patients with T2 classification (patches or plaques covering ≥10% of the skin surface) had worse PFS than patients with T1 classification (<10% involvement). The presence of plaques (T1b/T2b 13 ) was significantly associated with worse PFS compared to patches only. No cases of MF/SS-associated deaths were observed in patients with earlystage disease and T1 classification or patch-only disease (T1a/ T2a) (Fig. 2a) . FMF was associated with poor DSS in early-stage MF/SS (Fig. 2b) . In the late-stage group, elevated LDH was significantly associated with poor OS. Gender, and N and B classifications were not associated with survival or progression in univariate analysis. In multivariate analysis for OS in the early-stage group, T2 classification was associated with worse OS compared to T1. In the late-stage group, female patients had better OS and B1/B2 classification was associated with worse OS compared to B0, while elevated LDH was no longer associated with worse OS in a multivariate analysis.
Discussion
Disease progression in MF usually occurs as a slow evolution from patches and plaques to tumors and to extracutaneous disease with possibly fatal outcomes. While the vast majority of patients with early-stage MF will not progress to late-stage disease, such progression may arise in 5-10% of patients with clinical stage IA and in 17-39% with stage IB. 7 Prognostic factors outside the staging system may assist in the management of MF/SS by identifying patients with a potentially poor prognosis.
Older age is a known risk factor for MF/SS development and has been reported as associated with disease progression and poor outcomes. 5, 9 It has been debated whether it is an independent adverse prognostic factor 14 or whether older patients have a propensity to present with advanced disease stages. 4, 8, 15 The association between older age and OS was reported in several single-centre studies, Elderly patients with MF/SS cohort studies that reported on a significant association between old age and OS failed to do so for DSS. 17, 19, 25 In other studies, older age was correlated with poor DSS in univariate analysis but not in multivariate analysis. 7, 22 In our study in elderly patients, advanced age was associated with reduced OS, but not with DSS or PFS in both univariate and multivariate analysis. We observed that 76% of the patients who were diagnosed at the age of 65 years or older were diagnosed with early-stage MF/ SS, mainly clinical stages IA (44%) and IB (31%). As expected, the elderly patients with late-stage disease had significantly worse OS, DSS and PFS compared to those with early-stage disease.
No MF/SS-associated mortality occurred among elderly patients who presented with clinical stage IA, <10% total skin surface involvement (T1 classification) or early-stage patch disease without plaques (T1a/T2a), and progression of disease was rarely seen in these patients. In early-stage disease, T2 classification and plaques were found to have prognostic implications for risk of progression in univariate analysis and T2 classification association was also confirmed in multivariate analysis. FMF was shown to be a predictor of poor DSS among elderly patients with early-stage MF/SS; however, FMF was not associated with worse outcomes when the entire cohort was analysed. The latter finding can be supported by recent reports in the literature on the heterogeneous outcomes of FMF and the existence of folliculotropic subtypes that may have a favourable prognosis. 23, 26 In the elderly patients with late-stage disease, elevated LDH was identified in univariate analysis along with male gender and B1/B2 classifications that were identified in multivariate analysis -all were associated with reduced OS and none was found to have prognostic implications for DSS or PFS in the late-stage group.
Large cell transformation, defined as >25% large cells of atypical lymphocytes on histopathology, has been shown to be a poor prognostic factor in MF/SS.
14 Our analysis showed that the development of LCT was strongly associated with poor survival in MF/SS in both univariate and multivariate analysis. Patients who presented with LCT at diagnosis did not experience worse outcomes, and we have previously shown that patients presenting with LCT at diagnosis have better survival than those who initially present with a small cell phenotype and later develop LCT. 27 Numerous studies have attempted to validate prognostic factors and tools to be used in MF/SS. 14 Further prospective multicentre studies of larger patient cohorts are ongoing and are expected to further identify adverse prognostic factors and lead to reliable prognostic indexes in MF/SS. The retrospective nature of the data collection is a limitation of this study. Our cohort consisted of patients seen at a single tertiary cancer centre, and although our study population consisted of a heterogeneous group of elderly patients with earlyand late-stage MF/SS, a referral bias might exist towards patients with more advanced disease. However, in an elderly population, the bias might alternatively be towards patients who have lower disease burden and better functional ability to reach a tertiary referral centre.
In summary, our results show that advanced age is not associated with poor DSS or PFS in patients who are diagnosed with MF/SS older than 65 years. Elderly patients with earlystage disease who present with <10% involvement of the total skin surface or with patch-only disease (T1a, T1b, T2a) have an excellent prognosis and may be followed and treated similar to younger patients with early-stage disease. Patients with earlystage MF, who are diagnosed with the presence of FMF or plaque disease, should be monitored carefully for disease progression. In addition, the development of LCT is significantly associated with poor survival in elderly patients with MF/SS and should be looked for during their follow-up. The development of a prospectively validated prognostic index in MF/SS will be of great aid in the management of elderly patients with MF/SS. 
